Scientific Tracks Abstracts: J Cancer Sci Ther
Within the next 5 years, clinicians will be implementing targeted therapies based on the presence of specific biomarkers. Labs will be diagnosing cancer via liquid biopsies using blood or urine specimens, followed by locating the cancer and treating it using targeted therapy directed at the molecular mechanisms driving the disease. We as pathologist applaud the rigorous scientific methodology with all its advantages and disadvantages, but all these biomarkers provide only risk categories and numerical score for risk of recurrence or patient├ó┬?┬?s responsiveness to certain therapy. Yet, the decision is ├ó┬?┬?human-based├ó┬?┬? consideration involving oncologist-pathologist agreement on managing patient care unifying patient├ó┬?┬?s clinical presentation, molecular subtyping with standart clinicopathologic classification. How does the concept of personalized medicine affect pathology. What will be the primary role of a pathologist in 5 or 10 years? What current technologies in pathology are already absorbed by other specialties and what technologies could pathology absorb? If pathology goes for the change is it possible re-program our knowledge and capacity? The presentation focuses on the several options in the face of pathology necessary to keep path with the recent molecular techniques.
Diana Stanoeva has completed her PhD at the age of 35 years from Medical University in the city of Plovdiv, Bulgaria and is an Associate Professor at the same university. She is a Staff Pathologist at Histogenex, Antwerpen, Belgium – a premier companion diagnostic center. She has published more than 25 papers in local and international journals.
Cancer Science & Therapy received 3644 citations as per Google Scholar report